Denosumab-induced osteonecrosis of the jawa case report
- Rubio Ramírez, Lourdes 1
- Serrano Sánchez-Rey, Mª Cristina 1
- López-Pintor Muñoz, Rosa Mª 1
- De Arriba de la Fuente, Lorenzo 1
-
1
Universidad Complutense de Madrid
info
ISSN: 1697-6398, 1697-641X
Año de publicación: 2017
Volumen: 14
Número: 4
Páginas: 48-54
Tipo: Artículo
Otras publicaciones en: Científica dental: Revista científica de formación continuada
Resumen
Osteonecrosis of the jaw (ONJ) induced by antiresorptive drugs, mainly bisphosphonates (BP), is widely described in the scientific literature. In recent years, there have been reports of ONJ induced by other antiresorptive drugs such as Denosumab, Bevacizumab and Sunitinib used in cancer patients. Denosumab is a monoclonal antibody used in the treatment of osteoporosis and in the prevention of fracturesfollowing treatment ofsome types of cancer. In this article, we present the case of a patient who developed ONJ. The patient had periodontal disease and osteoporosis, which had been treated for years with Alendronate (oral bisphosphonate) and currentlywithDenosumab. In addition,she had a poorly adapted removable prosthesis. This paper discusses the risk of ONJ associated with such drugs, and the possible influence of certain localfactors on the occurrence of this condition, as well as the preventive and therapeutic measures thatshould be adopted in these cases.